Real‐World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First‐line Therapies for Medicare Patients 65 Years and Older With Advanced Non–small‐cell Lung Cancer: A Retrospective Study

[1]  D. Carbone,et al.  Real‐World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second‐Line Therapies for Medicare Patients With Advanced Non–Small‐Cell Lung Cancer , 2018, Clinical lung cancer.

[2]  W. John,et al.  Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients , 2017, Journal of medical economics.

[3]  N. Rashid,et al.  Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer. , 2017, Journal of managed care & specialty pharmacy.

[4]  Edward S. Kim,et al.  Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  C. Ferreira,et al.  Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2. , 2015, Lung cancer.

[6]  D. Carbone,et al.  Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  G. Pilkington,et al.  A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer , 2015, Thorax.

[8]  K. Davis,et al.  Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer. , 2015, Lung cancer.

[9]  S. J. Henley,et al.  Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004-2009. , 2014, Lung cancer.

[10]  T. Čufer,et al.  Update on systemic therapy of advanced non-small-cell lung cancer , 2014, Expert review of anticancer therapy.

[11]  A. Abernethy,et al.  Redistribution of Health Care Costs after the Adoption of Positron Emission Tomography among Medicare Beneficiaries with Non–Small-Cell Lung Cancer, 1998–2005 , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  Mark R. Green,et al.  Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting. , 2013, Lung cancer.

[13]  H. Henk,et al.  Treatment patterns and healthcare costs among patients with advanced non-small-cell lung cancer , 2013 .

[14]  Tanja Cufer,et al.  Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. , 2013, European Journal of Cancer.

[15]  G. Pilkington,et al.  Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review. , 2013, Health technology assessment.

[16]  Nikki M. Carroll,et al.  Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network. , 2012, Lung cancer.

[17]  C. Reyes,et al.  Costs and Clinical Outcomes among Patients with Second-Line Non-small Cell Lung Cancer in the Outpatient Community Setting , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  G. Oster,et al.  Healthcare costs in patients with metastatic lung cancer receiving chemotherapy , 2011, BMC health services research.

[19]  U. Gatzemeier,et al.  Characteristics, treatment patterns and outcomes of patients with small cell lung cancer--a retrospective single institution analysis. , 2011, Lung cancer.

[20]  Eric J Feuer,et al.  Projections of the cost of cancer care in the United States: 2010-2020. , 2011, Journal of the National Cancer Institute.

[21]  S. Ramsey.  Economics and the new generation of targeted therapies for non-small cell lung cancer. , 2010, Journal of the National Cancer Institute.

[22]  K. Kahn,et al.  Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Stokes,et al.  Neutropenia-Related Costs in Patients Treated with First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer , 2009, Journal of managed care pharmacy : JMCP.

[24]  D. Lubeck,et al.  Second-line and third-line chemotherapy for lung cancer: use and cost. , 2008, The American journal of managed care.

[25]  L. Garrison,et al.  Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[26]  Lee Bowman,et al.  The economic burden of lung cancer and the associated costs of treatment failure in the United States. , 2005, Lung cancer.

[27]  Ruth Etzioni,et al.  Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  W. Crown,et al.  Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  G. Scagliotti,et al.  Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Deborah Schrag,et al.  Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.

[31]  S. Rodenhuis,et al.  The molecular genetics of human lung cancer. , 1989, The European respiratory journal.

[32]  C. Rudin,et al.  Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  M. Edelman,et al.  Assessing functional status and the survival benefit of chemotherapy for advanced non-small cell lung cancer using administrative claims data. , 2015, Lung cancer.

[34]  C. Earle,et al.  Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.